Technical Analysis for IMVT - Immunovant, Inc.

Grade Last Price % Change Price Change
F 15.9 2.45% 0.38
IMVT closed up 2.45 percent on Thursday, April 22, 2021, on 33 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical IMVT trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Pocket Pivot Bullish Swing Setup 2.45%
Bullish Engulfing Bullish 3.72%
Stochastic Reached Oversold Weakness 3.72%
Outside Day Range Expansion 3.72%
Oversold Stochastic Weakness 3.72%
Down 3 Days in a Row Weakness 4.40%
20 DMA Resistance Bearish 3.11%
Older End-of-Day Signals for IMVT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 21 hours ago
Rose Above 20 DMA about 23 hours ago
Rose Above 10 DMA about 23 hours ago
Rose Above Previous Day's High about 23 hours ago
20 DMA Resistance about 23 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Eye Immune System Antibodies Autoimmune Diseases Monoclonal Antibody Monoclonal Antibodies Autoimmune Disease Thyroid Anemia Eye Disease Transfusion Medicine Treatment Of Autoimmune Disease Treatment Of Autoimmune Diseases Myasthenia Myasthenia Gravis Acquired Hemolytic Anemia Roivant Sciences Thyroid Eye Disease Treatment Of Myasthenia Gravis

Is IMVT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Apr 20 Last Chance to Actively Participate: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. (IMVT) Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
Apr 20 INVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 20 IMVT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
Apr 20 DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Apr 19 SHAREHOLDER DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses to Contact the Firm
Apr 19 IMVT Deadline Tomorrow: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
Apr 19 APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.
Apr 19 DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Apr 18 IMVT Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021
Apr 16 SHAREHOLDER ALERT: Holzer & Holzer Encourages Immunovant Investors With Significant Losses to Contact the Firm
See more IMVT news...

Indicators

Indicator Value
52 Week High 53.75
52 Week Low 11.8
Average Volume 1,444,671
200-Day Moving Average 33.16
50-Day Moving Average 16.46
20-Day Moving Average 15.70
10-Day Moving Average 15.56
Average True Range 0.87
ADX 25.42
+DI 23.70
-DI 28.60
Chandelier Exit (Long, 3 ATRs ) 14.53
Chandelier Exit (Short, 3 ATRs ) 16.73
Upper Bollinger Band 16.63
Lower Bollinger Band 14.76
Percent B (%b) 0.61
BandWidth 11.91
MACD Line -0.61
MACD Signal Line -0.83
MACD Histogram 0.2142
Fundamentals Value
Market Cap 1.56 Billion
Num Shares 97.9 Million
EPS -0.25
Price-to-Earnings (P/E) Ratio -62.62
Price-to-Sales 0.00
Price-to-Book 11.13
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.22
Resistance 3 (R3) 17.19 16.72 17.00
Resistance 2 (R2) 16.72 16.38 16.74 16.93
Resistance 1 (R1) 16.31 16.18 16.52 16.34 16.85
Pivot Point 15.84 15.84 15.94 15.86 15.84
Support 1 (S1) 15.43 15.50 15.64 15.46 14.95
Support 2 (S2) 14.96 15.30 14.98 14.87
Support 3 (S3) 14.55 14.96 14.80
Support 4 (S4) 14.58